Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Tirzepatide carries a boxed warning about thyroid C-cell tumors in rodents and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
A multivitamin or targeted supplements for deficiencies can make up the difference
It is either administered orally or through an injection process
But studies published in 2024 showed there was little to no increased risk of contracting thyroid cancer while on these drugs
US$ 20.07
US$ 26.69
US$ 22.06
US$ 29.78
